Tadaaki Yamada

6.2k citations

212 papers · 3.8k indexed · h-index 34

Oncology top 1%
- Lung Cancer Research Studies 59
- Cancer Immunotherapy and Biomarkers 38
- Colorectal Cancer Treatments and Studies 13
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 102
- Lung Cancer Diagnosis and Treatment 22
Gastroenterology top 2%
- Gastrointestinal motility and disorders 13
Cancer Research top 5%
Hepatology top 5%
Epidemiology
- Neuroendocrine Tumor Research Advances 18
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 15

Co-authors: Seiji Yano Shinji Takeuchi Koichi Takayama Kunio Matsumoto Junji Uchino Yoshiko KanekoWei WangYasuhiko Nishioka
Cited by: Oncology Pulmonary and Respiratory Medicine Gastroenterology
Journals: Journal of Clinical Oncology (5 papers)SHILAP Revista de lepidopterología (1 paper)Gastroenterology (3 papers)
Partner nations: Japan United States China

In The Last Decade

Tadaaki Yamada

204 papers receiving 3.7k citations

Peers

Countries citing papers authored by Tadaaki Yamada

Since Specialization

Citations

This map shows the geographic impact of Tadaaki Yamada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadaaki Yamada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadaaki Yamada more than expected).

Fields of papers citing papers by Tadaaki Yamada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadaaki Yamada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadaaki Yamada. The network helps show where Tadaaki Yamada may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Tadaaki Yamada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tadaaki Yamada Line = papers co-authored together Tadaaki Yamada links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma Cancer Genomics & Proteomics ·Daiki Shimizu,MIKU ISHIBASHI,Tadaaki Yamada,Yuki Toda,Shigekuni Hosogi,Eishi Ashihara	2024	3
2	Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% JTO Clinical and Research Reports ·Yoshihito Kogure,Hiroya Hashimoto,Haruko Daga,Yasushi Fukuda,Akihiro Bessho,Tadaaki Yamada,Yukihiro Toi,Tomoki Kimura,Hiroshige Yoshioka,Koichi Azuma,Naoki Furuya,Yasutaka Fukui,Akiko Saito,Nobuyuki Yamamoto,Hideo Saka,Masashi Kondo	2024	0
3	The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review Translational Lung Cancer Research ·Satomi Morita-Tanaka,Tadaaki Yamada,Koichi Takayama	2023	20
4	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice Molecular Cancer Therapeutics ·Rong Wang,Tadaaki Yamada,Sachiko Arai,Koji Fukuda,Hirokazu Taniguchi,Azusa Tanimoto,Akihiro Nishiyama,Shinji Takeuchi,Kaname Yamashita,Koshiro Ohtsubo,Junji Matsui,Naoyoshi Onoda,Eishu Hirata,Shu Taira,Seiji Yano	2019	20
5	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model Clinical Cancer Research ·Akihiro Nishiyama,Tadaaki Yamada,Kenji Kita,Rong Wang,Sachiko Arai,Koji Fukuda,Azusa Tanimoto,Shinji Takeuchi,Shoichiro Tange,Atsushi Tajima,Noritaka Furuya,Takayoshi Kinoshita,Seiji Yano	2018	22
6	Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study Pain ·Lynn R. Webster,Srinivas Nalamachu,Bart Morlion,Jyotsna Reddy,Yuko Baba,Tadaaki Yamada,Juan Camilo Arjona Ferreira	2018	68
7	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations Molecular Cancer Therapeutics ·Tadaaki Yamada,Joseph M. Amann,Azusa Tanimoto,Hirokazu Taniguchi,Takehito Shukuya,Cynthia Timmers,Seiji Yano,Konstantin Shilo,David P. Carbone	2017	31
8	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer Molecular Cancer Therapeutics ·Shigeki Nanjo,Sachiko Arai,Wei Wang,Shinji Takeuchi,Tadaaki Yamada,Akito Hata,Nobuyuki Katakami,Yasunori Okada,Seiji Yano	2017	47
9	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer Clinical Cancer Research ·Azusa Tanimoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Tadaaki Yamada,Xavier Roca,S. Tiong Ong,Seiji Yano	2016	71
10	A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain Pain Medicine ·Lynn R. Webster,Tadaaki Yamada,Juan Camilo Arjona Ferreira	2016	51
11	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma Cancer Research ·Jacob M. Kaufman,Tadaaki Yamada,Kyungho Park,Cynthia Timmers,Joseph M. Amann,David P. Carbone	2016	19
12	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma Cancer Research ·Tadaaki Yamada,Joseph M. Amann,Koji Fukuda,Shinji Takeuchi,Naoya Fujita,Hisanori Uehara,Shotaro Iwakiri,Kazumi Itoi,Konstantin Shilo,Seiji Yano,David P. Carbone	2015	17
13	EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition Cancer Research ·Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Yoshitaka Sekido,Seiji Yano	2013	136
14	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer Molecular Cancer Therapeutics ·Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Shigeki Nanjo,Daisuke Ishikawa,Takako Sano,Kenji Kita,Takahiro Nakamura,Kunio Matsumoto,Kenichi Suda,Tetsuya Mitsudomi,Yoshitaka Sekido,Toshimitsu Uenaka,Seiji Yano	2012	74
15	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer Clinical Cancer Research ·Wei Wang,Qi Li,Shinji Takeuchi,Tadaaki Yamada,Hitomi Koizumi,Takahiro Nakamura,Kunio Matsumoto,Naofumi Mukaida,Yasuhiko Nishioka,Saburo Sone,Takayuki Nakagawa,Toshimitsu Uenaka,Seiji Yano	2012	76
16	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells Clinical Cancer Research ·Tadaaki Yamada,Shinji Takeuchi,Junya Nakade,Kenji Kita,Takayuki Nakagawa,Shigeki Nanjo,Takahiro Nakamura,Kunio Matsumoto,Manabu Soda,Hiroyuki Mano,Toshimitsu Uenaka,Seiji Yano	2012	93
17	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Clinical Cancer Research ·Ivan Donev,Wei Wang,Tadaaki Yamada,Qi Li,Shinji Takeuchi,Kunio Matsumoto,Takao Yamori,Yasuhiko Nishioka,Saburo Sone,Seiji Yano	2011	93
18	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor Molecular Cancer Therapeutics ·Hirokazu Ogino,Masaki Hanibuchi,Soji Kakiuchi,Van The Trung,Hisatsugu Goto,Kenji Ikuta,Tadaaki Yamada,Hisanori Uehara,Akihiko Tsuruoka,Toshimitsu Uenaka,Wei Wang,Qi Li,Shinji Takeuchi,Seiji Yano,Yasuhiko Nishioka,Saburo Sone	2011	16
19	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR -T790M Mutant Lung Cancer Clinical Cancer Research ·Tadaaki Yamada,Kunio Matsumoto,Wei Wang,Qi Li,Yasuhiko Nishioka,Yoshitaka Sekido,Saburo Sone,Seiji Yano	2009	85
20	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Clinical Cancer Research ·Wei Wang,Qi Li,Tadaaki Yamada,Kunio Matsumoto,Isao Matsumoto,Makoto Oda,Go Watanabe,Yoshiyuki Kayano,Yasuhiko Nishioka,Saburo Sone,Seiji Yano	2009	231

About Tadaaki Yamada

Tadaaki Yamada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 212 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (59 papers), Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Diagnosis and Treatment (22 papers), Neuroendocrine Tumor Research Advances (18 papers), PI3K/AKT/mTOR signaling in cancer (15 papers), Colorectal Cancer Treatments and Studies (13 papers) and Gastrointestinal motility and disorders (13 papers). The work is most often cited by research in Oncology (1.9k citations), Pulmonary and Respiratory Medicine (1.7k citations) and Gastroenterology (261 citations). Tadaaki Yamada has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Seiji Yano, Shinji Takeuchi, Koichi Takayama, Kunio Matsumoto, Junji Uchino, Yoshiko Kaneko, Wei Wang, Yasuhiko Nishioka, Yusuke Chihara and Saburo Sone. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact